Drug intelligence / Profile preview

epi-reevesioside F

Development stage: Preclinical
Modality: Small Molecules

Overview

**epi-reevesioside F** is a natural small molecule type A cardenolide, isolated from plants of the Reevesia genus. It exhibits potent cytotoxic activity against various cancer cell lines and acts primarily as a Na+/K+-ATPase inhibitor, leading to cytosolic acidification, activation of Bak, and induction of apoptosis in tumor cells, including glioblastoma[8][6]. It is not an approved pharmaceutical agent and has been investigated preclinically for its antitumor effects.

Other names: epi-reevesioside F

Targets

ATP1A (Sodium/potassium-transporting ATPase)

Beyond the preview

Go deeper on epi-reevesioside F.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on epi-reevesioside F.

Explore the full profile